Category: Uncategorized

BEIJING, Sept 9 (Bernama-GLOBE NEWSWIRE) — George Clinical, a global clinical research organization with an extensive presence throughout the Asia-Pacific region, continues to expand the organization’s team in China with the addition of Helen Xu as Project Director and Cell Gene Therapy Head. She will be based in Beijing and joins a rapidly growing team responsible for expanding clinical research activity in China with biopharmaceutical, medical device and diagnostic sponsors.   

Dr. Xu obtained her MD in clinical medicine from Peking University Health Center. She is a licensed physician specialized in central nervous system (CNS) and has worked in the hospital setting for four years. Dr. Xu entered the pharmaceutical industry in 2007 starting as a clinical research associate (CRA) and has since accumulated 15 years of valuable clinical research experience in China. 

“I am sure Helen will make an incredibly valuable contribution to the growth and development of clinical research operations and cell gene therapy studies across China,” said Zhenfei Yin, country head and regional head project operations, China.

Before joining George Clinical, Dr. Xu had served GSK, BI, Wuxiapp, a Chinese clinical research organization, CASI, and Carsgen, a CAR-T biotech firm. Her clinical trial experience covers the whole development lifecycle starting from phase I through PMS, the majority of the trial experiences being with pivotal trials. Therapeutic areas of expertise include cell therapy, immunotherapies, blood tumors (MM, AML, thalassemia), solid tumors (lymphoma, gastric and pancreatic cancer, prostate cancer, lung cancer), respiratory disease (IPF, asthma), SSc-ILD, CNS (stroke, schizophrenia, GAD), HCV, cirrhosis, psoriasis, and in vitro diagnostics (IVDs) devices. Her responsibilities spanned the full duration of studies from bid defense, strategic planning, feasibility, and start-up to project close-out. The majority of these pivotal global trials experienced global audits and authority inspections from entities such as FDA, EMA, and NMPA. 

Additional new team members will be joining the organization to support the team in China with medical expertise.

“With a growing presence across the country, it is an honor to be part of global CRO able to bring further clinical research to China that can positively impact cancer care around the world,” Xu said.

About George Clinical

George Clinical is a leading global clinical research organization founded in Asia-Pacific driven by scientific expertise and operational excellence. With over 20 years of experience and more than 400 people managing 39 geographical locations throughout the Asia-Pacific region, USA, and Europe, George Clinical provides the full range of clinical trial services to biopharmaceutical, medical device, and diagnostic customers, for all trial phases, registration and post-marketing trials.    

LinkedIn: https://www.linkedin.com/company/george-clinical-pty-ltd

Twitter: https://twitter.com/george_clinical

Facebook: https://www.facebook.com/georgeclinical

Wechat: https://mp.weixin.qq.com/. 

Donna McDonnell
George Clinical
901-229-5345
dmcdonnell@georgeclinical.com

Source: George Clinical

–BERNAMA

· idolplus, a Korean media platform for K-pop entertainers, launched globally
· This web service released in six languages, including English, Chinese and Japanese, will target American and Asian markets with sizable K-pop fandoms
· An event to celebrate its global launching and official TMA idolplus Popularity Award voting will be held

SEOUL, South Korea, Sept 8 (Bernama-BUSINESS WIRE) — LG Uplus (CEO: Hyeon-sik Hwang) (KRX: 032640) changed the name of its media platform for K-pop entertainers, U+ idol Live, to idolplus, and launched a web service in six languages, including English, Chinese and Japanese.

idolplus is a live K-pop performance broadcasting platform launched in 2018 under the name of U+ idol Live. It has established itself as a media platform specializing in K-pop entertainers by continuously expanding contents for K-pop fans to approximately 35,000. In addition to original contents featuring popular K-pop entertainers, famous concerts and award shows can be watched for free on the platform.

The key contents include “IDOLLIVE School: Searching for IDOLLIVE School Ambassador,” a show introducing K-pop entertainers’ talents, “IDOLWORKSHOP,” a workshop of K-pop entertainers as office workers for a day, and “The Door: To the Strange World,” a situation play-based mystery game variety series. A large number of K-pop entertainers and groups, such as NCT Dream, ITZY, VIVIZ, Kep1er and BTOB, have appeared on the shows.

idolplus offers not only a wide range of high-resolution and high-quality contents, including original shows, performances and award ceremonies, but also close-up camera views of each member of the K-pop groups. idolplus’ contents, which are available in six languages, that is Korean, English, Chinese, Japanese, Thai and Indonesian, will be continuously expanded. Free picture-in-picture (PIP) and background play functions are also provided.

From September 8 (Thu.) to 20 (Tue.), idolplus will hold an event to celebrate its global launching. Through a lottery, participants in the event will win tickets to the 2022 The Fact Music Award to be staged in Korea on October 8 (Sat.).

The TMA idolplus Popularity Award voting will also be held. This special prize awarded by idolplus and K-pop fans through voting will be presented to entertainers at the TMA Awards ceremony. Following preliminary voting to select candidates between September 1 (Thu.) and 12 (Mon.), the top 30 entertainers based on the number of votes won will enter the final round of voting. The final voting will open on September 13 (Tue.) and continue until October 4 (Tue.). All global fans can participate in the voting.

2022 TMA, which will be broadcast live on the idolplus webpage, is a festival of K-pop entertainers and fans across the world. In 2022, it will be held as an offline event for the first time in three and a half years. K-pop stars, such as Stray Kids, ITZY, (G)I-DLE, IVE, and THE BOYZ, are gearing up to give awesome performances at the event.

idolplus Website: https://idolplus.com/
idolplus On Twitter: https://twitter.com/idolplus_offcl
idolplus On Instagram: https://www.instagram.com/idolplus_offcl/

Photos/Multimedia Gallery Available:
https://www.businesswire.com/news/home/52858059/en

Contact

LG Uplus idolplus
Hyunjun Song
+82-2-705-2279
idolplus.event@gmail.com

Source : LG Uplus

–BERNAMA

KUALA LUMPUR, Sept 5 (Bernama) — Gender equality is a prerequisite not only for human development— but sustainable economic growth according to Mary Kay Inc’s Chief Legal and Chief Diversity & Inclusion Officer, Julia A. Simon.

She made the statement on the release of the 2022 World Economic Forum’s Global Gender Gap Report.

According to a sobering finding from the World Economic Forum’s 2022 Global Gender Gap Report, gender parity is beyond reach in our lifetime.

In fact, according to the report, it will take 132 years for gender equality to become a reality and 151 years to close the economic participation and opportunity gender gap. Not a single country from the 146 examined has reached parity.

“That’s the bad news. The good news? There’s still time to change all that. The 2022 findings have shaken me, but they have not deterred me. Nor should they deter you,” Simon said in a statement.

A rich body of data shows that without gender parity, it is impossible to reduce poverty, attain food security, address climate impacts, or ensure a more peaceful and inclusive society.

To mitigate further backsliding, the structural barriers limiting women’s labour market participation, including their re-entry and retention in the workforce following COVID-19, must be addressed.

Targeted policies which support women’s talent development in the industries of the future, and which accelerate their advancement to leadership and management positions, are also needed.

She said the private sector had a critical role to play in addressing gender gaps in the workplace and in developing the pipeline of women for leadership positions.

“The time to act is now. Sitting on the sidelines and waiting 132 years is simply not an option. The Sustainable Development Impact Meeting on “Advancing Gender Equality”, which takes place in New York this month, is an opportunity for leaders from the public and private sector to identify tools and strategies to close the gender gap,” added Simon.

As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey through education, mentorship, advocacy, networking, and innovation.

— BERNAMA

KUALA LUMPUR, Sept 2 (Bernama) — Myriad Genetics Inc has announced Clinical Cancer Research, a journal of the American Association for Cancer Research, published a study showing the EndoPredict® breast cancer prognostic test significantly predicted distant recurrence in premenopausal women with ER+, HER2- early-stage breast cancer.

“This important publication on the new EndoPredict data demonstrates our ongoing commitment to advance precision medicine for patients with breast cancer,” said director of International Medical Affairs, Myriad Genetics, Dr Ralf Kronenwett.

According to a statement, this newly published study represents the first clinical validation of EndoPredict in a solely premenopausal population.

The study — first presented in an abstract at the 2021 ASCO Annual Meeting by Anastasia Constantinidou et al — examined tumour samples from 385 premenopausal women with ER+, HER2- primary breast cancer who had not received chemotherapy.

The results show EndoPredict accurately identified premenopausal women with and without affected lymph nodes who could safely avoid adjuvant chemotherapy as part of their treatment plans due to a very low recurrence risk.

The study shows that patients with EndoPredict low-risk scores had a 97 per cent distant recurrence free survival (DRFS) versus 76 per cent for high-risk patients.

Importantly, 19 per cent of node-positive premenopausal patients had EndoPredict low-risk scores with 100 per cent DRFS and were able to safely avoid chemotherapy and continue onto endocrine therapy alone.

Another key result from an exploratory subgroup analysis within the study found similar DRFS rates in low-risk patients with or without ovarian function suppression (OFS), with less than five per cent distant recurrence after 10 years in both groups.

More details at http://www.myriad.com.

— BERNAMA

KUALA LUMPUR, Sept 1 (Bernama) — Falcon experts from breeding farms worldwide praised this year’s International Saudi Falcons and Hunting Exhibition just two days into the event.

Now in its fourth year, the exhibition is larger than ever with visitation expected to top 500,000 over the course of the event running from Aug 25 to Sept 3, taking place in Riyadh.

Over 350 exhibitors are in attendance and many have shared their delight at the impact the exhibition is having on the industry.

Held at the Saudi Falcons Club HQ at Malham, attendees are greeted by the vast auditorium packed with falconry stalls, memorabilia, technology, equipment, photographs and items detailing the rich history of falconry in Saudi Arabia.

This include a huge stand showing the important work the Saudi Falcons Club does to promote the art of falconry and also the conservation of birds of prey.

According to a statement, international falcon breeders have been showcasing their stunning birds, with farms being represented from around the world.

Numerous breeders from Europe include the UK’s Fox and Desert falcons, France’s SB Falcons and Hura Falcons from Belgium. From further afield, Sullivan Mews are attending from USA while more locally Gulf Falcons are in attendance from Bahrain.

The exhibition has a special section dedicated solely to the history of falconry both in Saudi Arabia and around the world. This area is full of interactive exhibits in place to educate and inspire the next generation of falconers in the Middle East.

— BERNAMA